Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
17
Frequently Asked Questions
What is Market Cap of Celyad Oncology SA - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Celyad Oncology SA - ADR market cap is $15.91M.
What is the 52-week high for Celyad Oncology SA - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Celyad Oncology SA - ADR 52 week high is $3.07 as of September 14, 2025.
What is the 52-week low for Celyad Oncology SA - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Celyad Oncology SA - ADR 52 week low is $0.15 as of September 14, 2025.
What is Celyad Oncology SA - ADR stock price today?
Celyad Oncology SA - ADR stock price today is $0.60.
What was Celyad Oncology SA - ADR stock price yesterday?
Celyad Oncology SA - ADR stock price yesterday was $0.60.
What is the PE ratio of Celyad Oncology SA - ADR?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Celyad Oncology SA - ADR’s P/E ratio is -0.43.
What is the Price-to-Book ratio of Celyad Oncology SA - ADR?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Celyad Oncology SA - ADR P/B ratio is 12.1951.
What is Celyad Oncology SA - ADR's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Celyad Oncology SA - ADR's EBITDA is -0.76.
What is the 50-day moving average of Celyad Oncology SA - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Celyad Oncology SA - ADR 50-day moving average is $0.709.
How many employess does Celyad Oncology SA - ADR has?
